Pembrolizumab for first-line mRCC: Anecdotal evidence in real-world setting

At the 2023 SUO Annual Meeting, Grant Stewart, MD, PhD, discussed the potential of neoadjuvant therapy as a tool to help optimize the management of patients with localized kidney cancer.

“Obviously, patients benefit [from this regimen]. Not only can they enjoy longer life, but also their cancer is pretty much under control for a longer time, which is great,” says Karim Fizazi, MD, PhD

The phase 3 CAPTAIN trial was launched following the pivotal TACT trial, which showed that TULSA provided durable disease control with low toxicity at 3 years’ follow-up in men with localized prostate cancer.

"Jelmyto provides an effective and durable kidney-sparing treatment option and should be considered as primary therapy for adult patients with LG-UTUC,” said Phillip Pierorazio, MD.

“So I think what we can take away from this study is that just because your patient [has a higher BMI], doesn't mean that they're a poor candidate for a partial nephrectomy,” said Lachlan Shiver.

Pembrolizumab monotherapy continued to demonstrate durable complete responses, while rates of upstaging at the time of radical cystectomy were consistent with previous findings in the KEYNOTE-057 trial in patients with BCG-unresponsive NMIBC.